Pharma Faces: Demet Russ, Janssen Turkey
After an international career spanning 25 years, Demet Russ returned to her native Turkey to lead the Janssen affiliate during a tumultuous time and is aiming to give back to…
Deva, a local and rooted pharmaceutical company, has been operating in Turkey since 1958. With 3 production plants and approximately 1800 employees, Deva produces and markets drugs for human use, as well as APIs, veterinary drugs, colognes, and medical vials. It offers products in 13 diversified therapeutic areas ranging from oncology to cardiology, from respiratory system to nervous system. In addition, the company provides syrups, drops, sprays, creams, gels, suppositories, aerosol inhalers, tablets, film tablets, capsules, powder suspensions, and medical ampoules. Focusing on R&D, Deva develops innovative new forms and products of high added value at its R&D centre with a competent team of approximately 170 scientists.
With its growing international operations, Deva has around 300 licenses in many countries including EU countries such as Germany, the Netherlands, Switzerland and UK through agreements with pharmaceutical firms and distributors under the Deva brand name, as well as through license agreements; and provides contract manufacturing services. Deva Holding A.S is a subsidiary of EastPharma S.a.r.l.
Contact Details
Deva Holding AS
Halkali Merkez Mah. Press Express Avenue KÜÇÜKÇEKMECE / ISTANBUL
Tel:0 (212) 692 92 92 (PBX)
Fax:0 (212) 697 00 24
Email:The info@deva.com.tr
Website: www.deva.com.tr/
After an international career spanning 25 years, Demet Russ returned to her native Turkey to lead the Janssen affiliate during a tumultuous time and is aiming to give back to…
Avinash Potnis of Novartis Turkey discusses potential solutions to the country’s access and pricing dilemma which has raised concerns of system sustainability. Potnis also highlights the strengths of Turkey’s healthcare…
Ingrid Drechsel, head of Bayer’s pharma operations in Turkey and Iran, discusses the complexity of managing two countries under economic pressure and the advantages of Bayer’s longstanding relationship in both…
Menarini’s general manager for Turkey, the Middle East and Africa Uğur Bingöl discusses the Italian company’s restructuring in the region and its desire to replicate its success in Turkey across…
The secretary general for Turkey’s Pharmaceutical Manufacturers Association (IEIS), Savaş Malkoç, highlights their objective of increasing R&D expenditure and Turkey’s big opportunity ahead in biosimilars production. In addition, Malkoç discusses…
Janssen’s Managing Director for Turkey, Demet Russ, discusses her return to the country after 25 years abroad, having worked for Johnson & Johnson in different local, regional and global roles…
As one of the leading pharma companies in Turkey, DEVA is pioneering a new approach to generics in the country. Chairman of the Board and CEO Philipp Haas discusses the…
As COVID-19 began spreading through the world, the race to understand the disease by scientists and doctors took off. After just a few months, it became apparent that people with…
The president of the Turkish Society of Cardiology, Mustafa Kemal Erol, discusses the prevalence of cardiovascular disease, which accounts for over a third of deaths in Turkey, the improvements made…
AmCham Turkey’s executive director, Asli Özelli, examines the impact of US companies on the Turkish economy with over USD 50 billion in investment, their help during the pandemic, the chamber’s…
Dr Burak Cem, Novo Nordisk Vice President and General Manager for Turkey, outlines the company’s big bet on Turkey as a future regional hub through deep investment in clinical trials,…
Turkey’s former Minister of Health, Bülent Akarcali, outlines the country’s healthcare system evolution over the past decades, comparing the improvements to the difference between a Ford Model T to a…
See our Cookie Privacy Policy Here
